louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01999205: Moving To Business: Promoting Physical Activity and Reducing Sedentary Behavior in Office-based Companies in Finland
Official title: Moving To Business: Promoting Physical Activity and Reducing Sedentary Behavior in Office-based Companies in Finland (MTB)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Physical Activity
Sedentary Behavior
Work Ability
Keywords: workplace
intervention
physical activity
sedentary behavior
evaluation
Lead sponsor: UKK Institute
Sponsor class: OTHER
Collaborators: name: Finnish Institute of Occupational Health
name: Finnish Sports Confederation
name: Päijät-Hämeen Liikunta ja urheilu ry
name: Etelä-Karjalan Liikunta ja Urheilu ry
name: Hämeen Liikunta ja Urheilu ry
First posted: 2013-12-03
Enrollment: 396
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The participants are twelve small or middle-sized companies. Baseline information about the company's practices and employees' physical activity is collected in November 2013 with questionnaires and accelerometers. A team is nominated in each company to develop company's practices in relation to promoting physical activity and reducing sedentary behavior among employees. The teams are supported with materials and meetings and the opportunity to obtain physical activity services from the regional offices of the Finnish Sports Confederation. The development process is carried out in Fall 2013 and the actions to promote physical activity and to reduce sedentary behavior are implemented in the companies during spring and fall 2014. The follow-up evaluation with the same measures as at baseline will be conducted in November 2014 and depending on financing possibly also in November to assess the maintenance of the actions.


Eligibility criteria: Inclusion Criteria:

* companies: number of employees 15-150 (small or middle-sized)
* employees: all voluntary employees

Exclusion Criteria:

* companies: less than 15 or more than 150 employees
* employees: none

Primary outcomes:
measure: Physical activity and sedentary behavior
timeFrame: One year
Secondary outcomes:
measure: Work ability
timeFrame: One year
Other outcomes:
measure: Employees' participation in staff physical activity
timeFrame: One year
Locations:
city: Tampere
country: Finland
facility: The UKK Institute for Health Promotion Research
state: Pirkanmaa
Study officials:
affiliation: UKK Institute
name: Minna Aittasalo, DSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Aittasalo M, Livson M, Lusa S, Romo A, Vaha-Ypya H, Tokola K, Sievanen H, Manttari A, Vasankari T. Moving to business - changes in physical activity and sedentary behavior after multilevel intervention in small and medium-size workplaces. BMC Public Health. 2017 Apr 17;17(1):319. doi: 10.1186/s12889-017-4229-4.
Clinical trial NCT02980705: Efficacy and Safety Study of SUNPG1622
Official title: A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Lead sponsor: Sun Pharmaceutical Industries Limited
Sponsor class: INDUSTRY
First posted: 2016-12-02
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.


Eligibility criteria: Inclusion Criteria:

* Subject has provided informed written consent
* Subject is ≥ 18 years of age at time of Screening
* Subject must be on a stable dose of NSAID for ≥ 2 weeks prior to initiation of investigational product
* Subject has a negative test for TB within 4 weeks before initiating IMP

Exclusion Criteria:

* Subjects with known diagnosis of fibromyalgia or complex regional pain syndromes
* Active uveitis or symptomatic inflammatory bowel disease requiring therapy at screening
* Radiographic evidence of total ankylosis of the spine
* Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pre-treatment condition

Primary outcomes:
measure: Assessment of SpondyloArthritis International Society 20 Response Rates
timeFrame: Week 24
Secondary outcomes:
measure: Assessment of SpondyloArthritis International Society 20 Response Rates
timeFrame: Week 1, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Other outcomes:
Locations:
city: Middleburg Heights
country: United States
facility: SPARC Site 1
state: Ohio
city: Budapest
country: Hungary
facility: SPARC site 3
city: Elbląg
country: Poland
facility: SPARC site 3
city: A Coruña
country: Spain
facility: SPARC site 2
Study officials:
References:
Clinical trial NCT02924805: Telemedical Versus Conventional Emergency Care of Hypertensive Emergencies
Official title: Telemedical Versus Conventional Emergency Care of Hypertensive Emergencies and Urgencies
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertensive Emergency
Hypertensive Urgency
Lead sponsor: RWTH Aachen University
Sponsor class: OTHER
First posted: 2016-10-05
Enrollment: 331
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients whith a prehospital diagnosis of hypertensive emergency or urgency

Brief summary: Comparison of telemedical prehospital emergency care and conventional on-scene physician based care of hypertensive emergencies and urgencies. The adherence to current Guidelines should be researched.

Detailed description: Telemedically guided cases of hypertensive emergencies (april 2014 - March 2015) and urgencies are compared with a historical control group of conventional emergency medical service physician care on-scene for these scenarios. The historical control group is a time period prior to implementation of the telemedicine system and after a research project with a precursor telemedicine system. No telemedical support but only conventional on-scene EMS physician care was available (November 2013 - March 2014).

Eligibility criteria: Inclusion Criteria:

* prehospital diagnosis of hypertensive emergency of hypertensive urgency

Exclusion Criteria:

Prehospital diagnoses of:

* pulmonary edema
* aortic dissection
* acute coronary syndrome
* acute stroke
* acute respiratory insufficiency

Primary outcomes:
measure: Blood pressure difference between initial contact and emergency room handover
timeFrame: 2 hours
Secondary outcomes:
measure: Difference of heart rate between initial contact and emergency room handover
timeFrame: 2 hours
measure: Magnitude of blood pressure reduction using categories
timeFrame: 2 hours
Other outcomes:
measure: Analysis of administered antihypertensive agents
timeFrame: 2 hours
measure: context specific quality of medical history and documentation
timeFrame: 2 hours
Locations:
city: Aachen
country: Germany
facility: University Hospital Aachen
Study officials:
affiliation: University Hospital Aachen, Germany
name: Jörg Ch Brokmann, Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05840705: Approach Modification for Total Knee Arthroplasty in Morbidly Obese Patients
Official title: Approach Modification for Total Knee Arthroplasty in Morbidly Obese Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Arthropathy
Incision, Surgical
Obesity, Morbid
Keywords: Total knee arthroplasty
obese
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2023-05-03
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study provides a detailed description of a smaller incision with better visualization in total knee arthroplasty operations


Eligibility criteria: Inclusion Criteria:

* Morbid obese patients with body mass index more than 45 requiring total knee arthroplasty for any cause

Exclusion Criteria:

* candidates not meeting the inclusion criteria

Primary outcomes:
measure: Functional outcomes
timeFrame: 3 years
measure: length of skin incision
timeFrame: 7 years
measure: operative time
timeFrame: 7 years
Secondary outcomes:
measure: revision rate
timeFrame: 7 years
measure: wound complications
timeFrame: 7 years
measure: wound infection
timeFrame: 7 years
measure: Range of motion
timeFrame: 7 years
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ahmed Saeed
city: Cairo
country: Egypt
facility: Ahmed Saeed
Study officials:
References:
Clinical trial NCT00931905: Homeopathic Preparation Plumbum Metallicum for Lead Poisoning
Official title: Effectiveness of the Homeopathic Preparation Plumbum Metallicum in Decreasing Blood Levels in Exposed Workers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Lead Poisoning
Keywords: This study included workers exposed to lead.
Lead sponsor: Federal University of São Paulo
Sponsor class: OTHER
First posted: 2009-07-02
Enrollment: 113
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Saturnism, or lead poisoning, is defined by clinical symptoms (affecting primarily the nervous, hematopoietic, gastrointestinal, cardiovascular, musculoskeletal, renal and reproductive systems) compatible with exposure, in the short or long term, to lead or to its compounds, and can manifest as acute or chronic symptoms, pursuant to the intensity and duration of the signs and symptoms. Measuring serum concentration is the primary method for diagnosing and accompanying exposed workers. Presently, elevated lead counts are reversed by using drugs whose effectiveness is contested on various fronts. Experimental studies shows the efficacy of homeopathic preparations in controlling blood lead levels in laboratory animals, creating the need for controlled studies that evaluate the effectiveness and safety of these preparations in humans.The objective of this study was evaluate the effectiveness of the homeopathic preparation Plumbum metallicum in reducing the blood lead level of workers exposed to this metal.


Eligibility criteria: Inclusion Criteria:

* had not taken a leave of absence for any reason for a period greater than seven days in the 60 days prior to the intervention;
* where in good medical condition, as analyzed by their medical records and physical exam;
* had an initial blood lead level less than the maximum biological concentration permitted, which is 60µ/dL in Brazil.

Exclusion Criteria:

* workers who, in the last six months, had used medication that interferes/d with the level of lead in the blood, such as EDTA, BAL, penicillinase and DMSA;
* workers who had the right to vacation during the study period;
* workers who did not give their consent to participate in the study.

Primary outcomes:
measure: Effectiveness of the homeopathic preparation Plumbum metallicum in treating poisoning with respect to the decrease of the blood lead level of workers exposed to lead.
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Universidade Federal de Sao Paulo
Study officials:
affiliation: Federal University of São Paulo
name: Roberto Q Padilha, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Federal University of São Paulo
name: Rachel Riera, MD
role: STUDY_CHAIR
affiliation: Federal University of São Paulo
name: Alvaro N Atallah, phD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02953405: Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: MCA - Middle Cerebral Artery Dissection
Lead sponsor: Daewoong Pharmaceutical Co. LTD.
Sponsor class: INDUSTRY
First posted: 2016-11-02
Enrollment: 1000
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease

Brief summary: Prescription and Persistence of Antithrombotic agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients with MCA(Middle Cerebral Artery) Disease.


Eligibility criteria: Inclusion Criteria:

* 19 years later, men and women

Exclusion Criteria:

* Subject who is judged to be ineligible by investigator

Primary outcomes:
measure: Prescription status of Antithrombotic Agents
timeFrame: at 12 months after baseline(onset)
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: SNUBH
Study officials:
References:
Clinical trial NCT01563705: Prospective Follow-up of Patients With Glycogen Storage Disease Type III
Official title: Prospective Follow-up of Patients With Glycogen Storage Disease Type III
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Neuromuscular Disorders
Keywords: Neuromuscular Disorders
GSD III
glycogen storage disease
Lead sponsor: Institut de Myologie, France
Sponsor class: OTHER
First posted: 2012-03-27
Enrollment: 30
Sex: ALL
Minimum age (years): 10
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study is to improve knowledge of natural history and methods of monitoring the evolution of Glycogen storage disease type III regarding the muscle and to study the prospective approach of large series of patients, and using the same protocol for the follow up of the children and adults.


Eligibility criteria: Inclusion Criteria:

* patients with a debranching enzyme deficiency confirmed by enzymatic analysis (debranching enzyme deficiency).
* Written consent
* Age: at least 10 years
* Affiliated with a social security system

Exclusion Criteria:

* Pregnant and lactating women

Primary outcomes:
measure: Knee flexion and extension strength
timeFrame: at baseline
measure: Knee flexion and extension strength
timeFrame: 2 years after baseline
measure: Knee flexion and extension strength
timeFrame: 4 years after baseline
measure: Time to perform each motor function test
timeFrame: at baseline
measure: Time to perform each motor function test
timeFrame: 2 years after baseline
measure: Time to perform each motor function test
timeFrame: 4 years after baseline
measure: Gait speed measured during the 6 minutes walk test
timeFrame: at baseline
measure: Gait speed measured during the 6 minutes walk test
timeFrame: 2 years after baseline
measure: Gait speed measured during the 6 minutes walk test
timeFrame: 4 years after baseline
Secondary outcomes:
measure: Accelerometric variables measured for the 6 minutes walk test
timeFrame: At baseline
measure: Accelerometric variables measured for the 6 minutes walk test
timeFrame: 2 years after baseline
measure: Accelerometric variables measured for the 6 minutes walk test
timeFrame: 4 years after baseline
measure: NMR variables measured during each specific NMR sequence
timeFrame: at baseline
measure: NMR variables measured during each specific NMR sequence
timeFrame: 2 years after baseline
measure: NMR variables measured during each specific NMR sequence
timeFrame: 4 years after baseline
Other outcomes:
Locations:
city: Paris
country: France
facility: Institut de Myologie
Study officials:
References:
Clinical trial NCT00640705: Diclofenac Patch for Treatment of Mild to Moderate Ankle Sprain
Official title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Pain Due to Mild to Moderate Ankle Sprain.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Ankle Sprain
Lead sponsor: Cerimon Pharmaceuticals
Sponsor class: INDUSTRY
Collaborators: name: PPD Development, LP
First posted: 2008-03-21
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to assess the effectiveness of once daily application of a diclofenac sodium patch to the skin near or over the painful area. In this study, the location being studied will be either the left or right ankle.

The secondary purpose of this study is to assess the safety and tolerability of a diclofenac patch on the skin.

Detailed description: Cerimon Pharmaceuticals is investigating a topical patch formulation of diclofenac sodium containing 15 mg of diclofenac sodium for the local treatment of acute musculoskeletal pain.

Eligibility criteria: Inclusion Criteria:

* 18 to 75 years of age
* Has sustained a painful Grade 1 or 2 ankle sprain (Appendix H) no more than 48 hours prior to study entry
* Presence of pain of at least 5, with a maximum of 9, on an 11-point Numerical Rating Scale (NRS)

Exclusion Criteria:

* Grade 3 ankle sprain or bilateral sprain (see Appendix H)
* Previous injury to the same ankle within 3 months prior to current injury
* Aspirin or short half-life NSAID use within 12 hours, or longer half-life NSAID use within 24 hours prior to study entry (Appendix B)
* Opioid use within 24 hours prior to study entry
* Topical treatment, other than ice packs, applied to the painful region since time of injury
* A history of peptic ulcer disease within 1 year of study entry, any history of gastrointestinal bleeding or coagulation disorder
* A history of, or evidence for, underlying disease in the injured ankle, such as osteoarthritis or gout
* Clinically significant, poorly controlled pulmonary, gastrointestinal, hepatic, renal, endocrine, or cardiovascular disease
* A history of hypersensitivity to diclofenac or diclofenac-containing products
* A history of intolerance to acetaminophen (rescue medication in this trial)
* A history of skin sensitivity to adhesives (e.g. adhesive tape)
* Pregnant or breastfeeding women and women of child-bearing potential not using effective means of contraception

Primary outcomes:
measure: Assess the efficacy of diclofenac in subjects with mild to moderate ankle sprain.
timeFrame: 7 days
Secondary outcomes:
measure: Assess the safety and tolerability of diclofenac in subjects with mild to moderate ankle sprain.
timeFrame: 7 days
Other outcomes:
Locations:
city: Austin
country: United States
facility: PPD
state: Texas
Study officials:
affiliation: Cerimon Pharmaceuticals
name: Dan Levitt, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03372005: The Effect of Floorball on Health and Performance in Subjects With Lifestyle Diseases
Official title: The Effect of Floorball on Health Parameters and Performance in Subjects With Lifestyle Diseases
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Type2 Diabetes, Cardiovascular Diseases
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
First posted: 2017-12-13
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: To investigate the effect of floorball on health and performance in subjects with either type 2 diabetes or cardiovascular diseases.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with type 2 diabetes
* Diagnosed with a cardiovascular disease (bp \>140/90mmHg)
* Physical activity \<2 hours pr. week.
* Not participating in any regular physical activity the last 2 years

Exclusion Criteria:

* age \<18 years
* Injuries that prevent the subject from playing floorball
* Type 1 diabetics
* Alcohol \>14 units pr. week.
* Pregnancy
* Participation in other scientific studies
* Abuse of illegal drugs
* other known serious diseases

Primary outcomes:
measure: HbA1c
timeFrame: Changes from baseline measured after 12 weeks and 39 weeks
measure: Blood pressure
timeFrame: Changes from baseline measured after 12 weeks and 39 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: August Krogh Building
Study officials:
References:
Clinical trial NCT05194605: Predictive Models of Treatment Responses and Survival Outcomes in Patients With Osteosarcoma
Official title: Predictive Models of Treatment Responses and Survival Outcomes in Patients With Osteosarcoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Osteosarcoma
Lead sponsor: West China Hospital
Sponsor class: OTHER
First posted: 2022-01-18
Enrollment: 800
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with osteosarcoma who were diagnosed histologically with definite pathologic specimens.

Brief summary: The aim of this study was to developed and validated models to predict therapeutic responses and patients' survivals in patients with osteosarcoma and compared these models with currently available models.

Detailed description: The investigator performed a retrospective-prospective cohort study with the aim of developing and validating comprehensive models to predict treatment responses and survival outcomes in patients with biopsy-proven osteosarcoma. Secondly, the investigator aimed to compare the predictive accuracy with currently available noninvasive model.

Eligibility criteria: Inclusion Criteria:

* Receiving no treatment before diagnosis
* With written informed consent

Exclusion Criteria:

* Clinical data missing
* Without written informed consent

Primary outcomes:
measure: Treatment response
timeFrame: At least 1-year follow up
measure: Progression-free survival outcomes
timeFrame: At least 5-year follow up
measure: Overall survival outcomes
timeFrame: At least 5-year follow up
Secondary outcomes:
Other outcomes:
Locations:
city: Chengdu
country: China
facility: West China Hospital, Sichuan University
state: Sichuan
Study officials:
References: